TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.Submission of Matters to a Vote of Security Holders.
TG Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders on Wednesday, June 13, 2018 at the offices of its legal counsel, Alston & Bird LLP, 90 Park Avenue, New York, New York 10016 at 9:30 a.m. Eastern Standard Time. Stockholders representing 62,395,470, or 80.33%, of the 77,666,112 shares entitled to vote were present in person or by proxy. Proxies were solicited by the Company to Regulation 14A under the Securities Exchange Act of 1934, as amended. At the annual meeting, Proposals 1, 2, and 3 were approved. The proposals below are described in detail in the Company’s definitive proxy statement dated April 30, 2018 for the annual meeting.
The results are as follows:
Proposal 1
The following persons were nominated and elected directors:
|
Michael S. Weiss |
Laurence N. Charney |
William J. Kennedy |
Mark Schoenebaum, MD |
Yann Echelard |
Kenneth Hoberman |
Daniel Hume |
The shareholder voting for board members is summarized as follows:
|
Director |
Votes For |
Votes Withheld |
Abstentions |
Broker Non-Votes |
|
Michael S. Weiss |
34,700,747 |
4,776,720 |
0 |
22,918,003 |
|
Laurence N. Charney |
25,138,011 |
14,339,456 |
0 |
22,918,003 |
|
William J. Kennedy |
25,139,461 |
14,338,006 |
0 |
22,918,003 |
|
Mark Schoenebaum, MD |
22,987,997 |
16,489,470 |
0 |
22,918,003 |
|
Yann Echelard |
32,433,930 |
7,043,537 |
0 |
22,918,003 |
|
Kenneth Hoberman |
32,420,553 |
7,056,914 |
0 |
22,918,003 |
|
Daniel Hume |
32,433,698 |
7,043,769 |
0 |
22,918,003 |
All seven directors will serve on the board of directors of the Company (the “Board”) until the 2019 annual meeting.
Proposal 2
CohnReznick LLP was approved as the Company’s independent registered public accountant for the fiscal year ending December 31, 2018.
The votes cast were as follows:
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|
61,581,162 |
365,659 |
448,649 |
0 |
Proposal 3
The amendment to the Amended and Restated 2012 Incentive Plan (the “Plan”) was approved to increase the number of shares of common stock available for issuance under the Plan by 6,000,000.
The votes cast were as follows:
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|
33,670,966 |
5,283,744 |
522,757 |
22,918,003 |
About TG Therapeutics, Inc. (NASDAQ:TGTX)
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.